Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Danes improve treatment of life-threatening illnesses

This article was originally published in Clinica

Executive Summary

Denmark is to alter is regulations on the diagnosis and treatment of life-threatening illnesses as a result of discussions between the organisation of local councils (Amtsradsforeningen) and the government. Regulations which previously ensured that patients suffering from heart disease or breast, intestinal, lung or cervical cancer received priority treatment will, from September 1, be extended to include all cancer patients. The new measures mean that patients judged to be at risk will have to wait no more than two weeks for a preliminary examination, two weeks for treatment and four weeks for follow-up care. The regulations also allow for patients to be treated in other Danish counties or even broad, if their regional hospitals are either full or cannot provide the necessary facilities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT072632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel